Phase 2Terminated
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies
- Sponsor
- HemaQuest Pharmaceuticals Inc. (Industry)
- Enrollment
- 1 enrolled
- Conditions
- EBV Lymphomas; Lympho-proliferative Diseases
- Interventions
- Arginine Butyrate; Ganciclovir; Valganciclovir
- Ages
- children, adults, older adults
- Registry
- NCT00917826
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.
Primary outcomes
- Response Rate (using Revised Response Criteria for Malignant Lymphoma, Cheson et al., JCO 2007)
History
Last registry update
Primary completion
Registered
Started